EC Number   |
Application |
Reference |
|---|
    4.1.1.32 | drug development |
potential target for anti-diabetic drugs |
667839 |
| 4.1.1.32 | medicine |
chronic administration of phenobarbital reduces hepatic PEPCK mRNA in streptozotocin-induced diabetic and nondiabetic rats, and phenobarbital reduces blood glucose level in diabetic rats |
746970 |
| 4.1.1.32 | medicine |
inhibitors of PEPCK may be useful in the treatment of type II diabetes |
652878 |
| 4.1.1.32 | medicine |
plays a role in the development of type 2 diabetes |
678421 |
| 4.1.1.32 | pharmacology |
development of a PEPCK inhibitor may lead to a new therapeutic strategy for the treatment of type II diabetes |
652878 |
| 4.1.1.32 | pharmacology |
orally active compounds reversibly inhibiting PEPCK improve glucose homeostasis in type 2 diabetics |
650567 |
| 4.1.1.32 | synthesis |
heterlogous expression in the Escherichia coli dcuD mutant improves hydrogen and ethanol synthesis when grown in a glycerol-based medium. Hydrogen and ethanol specific productions and glycerol consumption increase by 2.46, 1.73 and 1.95 times, respectively, upon the expression |
748770 |
